[go: up one dir, main page]

IL109337A0 - Indole derivatives for use in migraine - Google Patents

Indole derivatives for use in migraine

Info

Publication number
IL109337A0
IL109337A0 IL10933794A IL10933794A IL109337A0 IL 109337 A0 IL109337 A0 IL 109337A0 IL 10933794 A IL10933794 A IL 10933794A IL 10933794 A IL10933794 A IL 10933794A IL 109337 A0 IL109337 A0 IL 109337A0
Authority
IL
Israel
Prior art keywords
pct
migraine
date oct
indole derivatives
sec
Prior art date
Application number
IL10933794A
Other languages
English (en)
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939308360A external-priority patent/GB9308360D0/en
Priority claimed from GB939324433A external-priority patent/GB9324433D0/en
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of IL109337A0 publication Critical patent/IL109337A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL10933794A 1993-04-22 1994-04-18 Indole derivatives for use in migraine IL109337A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939308360A GB9308360D0 (en) 1993-04-22 1993-04-22 Indoles
GB939324433A GB9324433D0 (en) 1993-11-27 1993-11-27 Indoles

Publications (1)

Publication Number Publication Date
IL109337A0 true IL109337A0 (en) 1994-07-31

Family

ID=26302791

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10933794A IL109337A0 (en) 1993-04-22 1994-04-18 Indole derivatives for use in migraine

Country Status (21)

Country Link
US (1) US5607960A (xx)
EP (1) EP0695301B1 (xx)
JP (1) JP2802169B2 (xx)
KR (1) KR960701865A (xx)
CN (1) CN1121348A (xx)
AT (1) ATE144773T1 (xx)
AU (1) AU6567094A (xx)
BR (1) BR9406481A (xx)
CA (1) CA2157397C (xx)
CZ (1) CZ274595A3 (xx)
DE (1) DE69400824T2 (xx)
DK (1) DK0695301T3 (xx)
ES (1) ES2094653T3 (xx)
FI (1) FI954944A0 (xx)
GR (1) GR3021804T3 (xx)
HU (1) HUT73807A (xx)
IL (1) IL109337A0 (xx)
NO (1) NO954168D0 (xx)
NZ (1) NZ265269A (xx)
PL (1) PL311204A1 (xx)
WO (1) WO1994024127A1 (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
WO1995006636A1 (en) * 1993-08-31 1995-03-09 Pfizer Inc. 5-arylindole derivatives
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420503D0 (en) * 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
WO1996029075A1 (en) * 1995-03-20 1996-09-26 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
WO1998011895A1 (en) * 1996-09-18 1998-03-26 Eli Lilly And Company A method for the prevention of migraine
WO1998023587A1 (en) * 1996-11-26 1998-06-04 Allelix Biopharmaceuticals Inc. 5-cyclo indole compounds as 5-ht1d receptor ligands
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
US5856510A (en) * 1996-12-16 1999-01-05 Allelix Biopharmaceuticals Inc. 5-alkenyl and 5-alkynyl indole compounds
GB9705035D0 (en) * 1997-03-11 1997-04-30 Pharmacia & Upjohn Spa Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation
EP0875513A1 (en) * 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
JP2001512727A (ja) * 1997-08-09 2001-08-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ−１受容体のリガンドとしてのニ環式化合物
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
NZ523436A (en) * 2000-07-21 2004-07-30 H Indole derivatives useful for the treatment of CNS discorders
US6489512B1 (en) 2002-06-21 2002-12-03 Rhodia Chirex Inc. Method for making aryl hydrazines and substituted indoles
CA2509225C (en) * 2002-12-10 2011-09-20 Guenter Hoelzemann Indol derivatives and their use as 5-ht ligands
WO2004056769A2 (en) * 2002-12-20 2004-07-08 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
ATE546134T1 (de) * 2002-12-26 2012-03-15 Pozen Inc Mehrschichtige dosierformen enthaltend naproxen und triptane
BRPI0410807A (pt) * 2003-06-06 2006-06-27 Glaxo Group Ltd composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005066157A1 (en) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
GB0807772D0 (en) * 2008-04-29 2008-06-04 Lectus Therapeutics Ltd Calcium ion modulators and uses thereof
FR2953720B1 (fr) * 2009-12-11 2012-05-11 Oreal Utilisation de derives de benzyloxy-ethylamines comme conservateur,
CN104557957B (zh) * 2013-10-09 2017-04-19 华东师范大学 螺‑氧化吲哚环氧乙烷衍生物的合成方法
CA3166940A1 (en) * 2020-02-04 2021-08-12 Abdelmalik Slassi 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8530507D0 (en) * 1985-12-11 1986-01-22 Glaxo Group Plc Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
DK0592438T5 (da) * 1990-10-15 1999-12-06 Pfizer Inc. Indolderivater

Also Published As

Publication number Publication date
EP0695301B1 (en) 1996-10-30
NO954168L (no) 1995-10-19
DE69400824T2 (de) 1997-03-13
PL311204A1 (en) 1996-02-05
KR960701865A (ko) 1996-03-28
FI954944A (fi) 1995-10-17
NO954168D0 (no) 1995-10-19
ATE144773T1 (de) 1996-11-15
GR3021804T3 (en) 1997-02-28
FI954944A0 (fi) 1995-10-17
ES2094653T3 (es) 1997-01-16
DE69400824D1 (de) 1996-12-05
BR9406481A (pt) 1996-01-09
CN1121348A (zh) 1996-04-24
NZ265269A (en) 1996-09-25
JPH08507083A (ja) 1996-07-30
HUT73807A (en) 1996-09-30
CA2157397C (en) 1999-07-06
DK0695301T3 (da) 1996-12-09
JP2802169B2 (ja) 1998-09-24
US5607960A (en) 1997-03-04
WO1994024127A1 (en) 1994-10-27
CA2157397A1 (en) 1994-10-27
AU6567094A (en) 1994-11-08
HU9501920D0 (en) 1995-09-28
EP0695301A1 (en) 1996-02-07
CZ274595A3 (en) 1996-03-13

Similar Documents

Publication Publication Date Title
IL109337A0 (en) Indole derivatives for use in migraine
EP0544819A4 (en) Indole derivatives which inhibit leukotriene biosynthesis
ES2121193T3 (es) Derivados de bencimidazoles.
FI970148A0 (fi) Heterosyklisten yhdisteiden käyttö dopamiini-D3-ligandeina
HU9503986D0 (en) Perhydroisoindole derivatives as p substance antagonists
BG102726A (en) Combined therapy for osteoporosis
IL115105A0 (en) Topical ketoconazole emulsions
NZ290387A (en) Substituted 1,2,4-triazole derivatives
AU4310097A (en) Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists
MY124078A (en) Eletriptan hydrobromide monohydrate
ATE197453T1 (de) Imidazol-, triazol- und tetrazolderivate
MY132066A (en) Pyrrolidinylmethylindole salt.
AU3267097A (en) Methanesulphonate salt of an arylpiperazine derived from tryptamine and its solvates for pharmaceutical use
SE9404438D0 (sv) New process
ES2181791T3 (es) Derivados de indol para el tratamiento de la migraña.
MY108739A (en) Imidazole, triazole and tetrazole derivatives
IL126548A0 (en) Use of aspirochlorine or derivatives thereof as immunosuppressive agents
GB9809555D0 (en) Use of neuropeptide Y receptor agonists for treating migraine
ES2070087A1 (es) Derivados de indol